Hepatic Matrix Gene Expression Remains Elevated Relative to Chow-Fed References During Semaglutide Treatment in Murine MASH: Associations with Human Fibrosis Stage
Year: 2026
Type: article
Abstract: Semaglutide improves metabolic dysfunction-associated steatohepatitis (MASH), but the extent of hepatic transcriptional recovery remains unclear. We compared predefined program scores between semaglutide-treated and healthy groups in three GAN diet-induced MASH mouse experiments and an independent Ldlr−/−.Leiden model. We examined cross-sectional associations between corresponding human orthologs and fibrosis stage in three liver-biopsy cohorts with no semaglutide treatment comparison. Treated-minus-healthy extracellular matrix (ECM) score differences were 0.57–0.89 mean log2 units in the original experiments and 0.79 (95% confidence interval 0.62–0.97) in the independent model. Collagen scores also remained elevated. In 206 human donors, ECM and collagen scores were 0.33 (95% CI 0.23–0.44) and 0.37 (0.27–0.47) standard deviations higher per fibrosis stage, respectively, with positive associations in the other cohorts. A broader mouse-derived residual signature closely tracked the disease-associated signature and provided little additional information beyond ECM in the external test. Matrix–program expression remained elevated relative to chow-fed references under continued disease-inducing diets.
Source: Biology
Authors: Qian Xu(Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft), Mingle Li(Data curation, Investigation, Software, Validation), Naxun Fan(Data curation, Validation), Feiyuan Yu(Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing)
Institutions: Shantou University, Shantou University Medical College
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,258
Awards: G1969447342, G8781649926
OpenAlex ID: W7233846472
